PTO-1595	01-12-2007
1/31/92	U.S. DEPARTMENT OF COM PATENT AND TRADEMARK
To the User of Detector	103361019 767 MM 11 74 K
1. Name of conveying part(ies): Lynne Botts and Bruce Botts	2. Name and address of receiving particles:     The Blaine Company, Inc. d/b/a/ Blaine Pharmace     Internal Address:
Additional name(s) of conveying parties att	
<ul> <li>3. Nature of Conveyance:</li> <li>Assignment</li> <li>Security Agreement</li> <li>Other:</li> </ul>	
Execution Date: <u>12/29/06</u>	Additional name(s) and address(es) attached? Yes X No
4. Application number(s) or patent number If this document is being filed together with	r(s): h a new application, the execution date of the application is:
A. Patent Application No.(s)	B. Patent No.(s) US 5,244,122 US 6,126,679 US 6,270,519
	Additional numbers attached? 🔲 Yes 🖾 No
<ol> <li>Names and address of party to whom co concerning document should be mailed:</li> </ol>	orrespondence       6. Total number of applications and patents involved:
	7. Total Fee (27 CFR 3.41) \$120.00
Name: <u>Joshua A. Lorentz</u> Internal Address: Dinsmore & S Street Address: 1900 Chemed 255 East Fifth City: Cincinnati State: Ohic	I Center h Street ☐ Please charge any deficiencies or credit any overpayment to deposit account ☐ Authorization to be charged to deposit account
	(Attach duplicate copy of this page if paying by deposit account)
	DO NOT USE THIS SPACE
9. Statement and signature.	and belief, the foregoing information is true and correct and any attached document.

,

PATENT REEL: 018777 FRAME: 0111

## <u>ASSIGNMENT OF PATENTS</u>

WHEREAS, LYNNE BOTTS and BRUCE BOTTS (collectively "Botts"), are the owners in the United States of America of all right, title and interest in United States Patent Nos. 5,244,122, 6,126,679 and 6,270,519, and all reissues, divisions, continuations, continuations in part, extensions, reexaminations and foreign counterparts thereof or thereon, all of which are listed in Exhibit 1 hereto ("Patents"). For purposes of this Assignment of Patents, the term Patents shall include any patent deriving from an application to be filed relating to the collar on the current bottle design, and, as to all of the foregoing, together with any and all reissues, divisions, continuations, continuations in part, extensions, divisional patents, reissues and reexaminations and foreign counterparts thereof or thereon.

WHEREAS, The Blaine Company, Inc. d/b/a Blaine Pharmaceuticals ("Blaine"), desires to acquire all of the rights to the Patents.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that for good and valuable consideration, the receipt of which is hereby acknowledged by Botts, Botts hereby assigns to Blaine Botts' entire right, title and interest in and to the Patents (including any patent deriving from an application to be filed relating to the collar on the current bottle design) and the right to recover for past infringement thereof, and Blaine hereby accepts such assignment from Botts, effective December 29, 2006. Further, Botts hereby covenants, agrees and undertakes to execute all applications, assignments, lawful oaths and any other papers which Blaine may deem necessary or desirable for securing to Blaine or for maintaining for Blaine the Patents hereby assigned, all without further compensation to Botts.

This Assignment of Patents is executed and delivered in accordance with, and pursuant to, the Asset Purchase Agreement dated as of December 29, 2006 (the "APA") and nothing in this Assignment of Patents shall extend, expand or limit the rights, remedies or obligations of Botts or Blaine under the APA.

THE BLAINE COMPANY, INC. d/b/a **BLAINE PHARMACEUTICALS** 

Name: Vincent J. Gilday Jr.

Title: Chief Operating Officer



**ROBERT WARNER OFF** ATTORNEY AT LAW Notary Public, State of Ohio My Commission Has No Expiration Section 147.03 R.C.

other R. WARNE off